CD19 / B-cell biology
Among the top 2 ranked therapeutic targets
Inebilizumab
Phase III efficacy
FDA approval in IgG4-RD · April 2025
AI-powered • Prospectively Validated •Industrial-Grade
The Decision IntelligencePlatform for Life Sciencesand Drug R&D
Simulate critical decisions before committing real-world time, capital, and patients.
Explore the Platform
- Human MechanisticDigital Twins
- Virtual PatientPopulations
- AI-PoweredDecision Making
- Regulatory-GradeEvidence
Prospective Prediction. Independent Clinical Validation.
A human multi-omics mechanistic model prospectively prioritized therapeutic mechanisms and predicted biological responses subsequently supported by independent clinical evidence.
Patient multi-omics data+AI + knowledge graph+Mechanistic modeling
Patient-level response prediction
Timestamped poster In Conferences
- PAGE
- ACOP
- NBC
TH2 / IL-4 signaling
Top-ranked mechanistic pathway
Dupilumab
Clinical improvement and reduced IgG4 in 4/5 patients
Independent case-series preprint · January 2026
Human Disease Mechanism as a Dynamic Executable System
Unlike correlation-based AI trained on historical data, our mechanistic digital twins model the biological mechanisms driving disease and patient response—turning critical decisions into testable virtual experiments.
Virtual Pathways
- Target proteins
- Receptors
- Signaling pathways
Virtual Cells
- Disease cells
- Healthy cells
- Immune cells
Virtual Organs
- Tumor microenvironment
- Disease organs
- Cell-cell interactions
Virtual Systems
- Systemic biology
- Pharmacology
- Peripheral immune system
Virtual Patient
- Biological heterogeneity
- Disease burden
- Response / resistance
The 6-Best Framework
A Single Platform. A powerful advantage across the entire R&D and investment lifecycle
Turn fragmented data into decision-ready insights and evidence for the highest-stakes choices in drug development
R&D Decisions
Which science should we bet on?
- Multiple targets
- Multiple modalities
- Competing assets
- Uncertain translation
Prioritize the most promising targets and assets
- Advance / Kill
- De-risk early
- Maximize ROI
Clinical Development
Optimize the strategy to win
- Patient selection
- Combination strategy
- Dose and schedule
- Indication and line of therapy
- Trial design and control arm
Optimal development strategy
- Right patients & indication
- Right combination
- Trial size reduction
- Higher probability of success
Capital Decisions
Maximize portfolio value
- Indication expansion
- Geographical expansion
- Lifecycle management
- BD / licensing evaluation
- Portfolio optimization
Identify new growth opportunities
- Indication expansion
- Franchise strategy
- BD and acquisition diligence
- Portfolio optimization
Higher probability of success, better clinical outcomes, and greater commercial value.
Explore the 6-Best Decisions
Pick Winners Earlier
De-risk targets, molecules and programs before major capital commitment.
Win the Market
Go to market faster with superior trial results for accelerated commercial success.
Maximize Asset Value
Generate quantitative evidence for licensing, indication expansion, and portfolio decisions.
Partners
Chosen by global industry leaders
Multiple global MNCs, biotechs, CROs and life science organizations trust Differentia to turn complex biological questions into auditable virtual experiments.
Best Target
The Challenge
No validated animal model for an inflammatory or infectious disease.
The Simulation
Simulate target efficacy, safety and combination strategies.
Eliminate Ineffective Targets Early
Best Target
The Challenge
No validated animal model for an inflammatory or infectious disease.
The Simulation
Simulate target efficacy, safety and combination strategies.
Eliminate Ineffective Targets Early
Best Molecule
The Challenge
Animal-to-human translation uncertainty for novel assets
The Simulation
Simulate candidate safety and efficacy in virtual patients against competitor molecule
Stop Inferior Assets Before Clinical Development
Best Dosing
The Challenge
Optimize dosing regimen
The Simulation
Simulate exposure, efficacy, toxicity and therapeutic window.
Precision-Designed Phase I-III Dosing
Best Trial Design
The Challenge
Slow enrollment
The Simulation
Simulate trial scenarios to optimize cohort size, design and outcomes.
Reduce 30%+ trial size - Preserve billions in revenue
Best Segmentation
The Challenge
Optimize Phase III to target best in class
The Simulation
Generate virtual patients from Phase I–II data; simulate subgroup efficacy, safety and outcomes
De-risked Phase III, target to be the market leader
Regulatory-grade by design
Rigorous Validation: Credible, Auditable, Regulatory-Ready
From mechanistic fidelity to clinical prediction: a 4-stage framework built for FDA MIDD alignment.
100%Explainable.
No black-box answer.
Every recommendation is connected to explicit mechanisms, evidence, assumptions, model boundaries and a traceable audit trail.
- 01Mechanistic Validity
- 02Historical Data Calibration
- 03External Validation
- 04Decision Robustness
Modelling aligned withregulatory standards &
compliance framework
- Global guidelineICH M15 aligned
- Governed records21 CFR Part 11 ready
- Regulatory pathwayFDA / EMA / CDE
One scientific foundation. Three decision domains.
R&D
Identify the best targets, molecules, dosing strategies, trials and patient populations.
Capital
Connect scientific evidence to asset prioritization, portfolio strategy, investment, licensing and M&A decisions.
Clinical
Over time, extend mechanistic digital twins toward precision medicine and individualized treatment decisions.
Start with the decision
Evaluate the decision before it becomes a real-world commitment
Whether you are evaluating a target, comparing candidates, selecting a regimen, designing a trial or defining a development population, Differentia can turn the available evidence into a controlled virtual experiment.